Schrödinger, Inc.

NASDAQ:SDGR

Medical - Healthcare Information Services

Healthcare
$27.20 +0.01%

+$0.00 today

Market cap
$1.79B
Beta
1.64
P/E (TTM)
-11.1
EPS (TTM)
-$1.40
52W Low $10.95High $23.75

Volume 1.18M

Average 1.35M

SDGR Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Schrödinger, Inc.NASDAQ: SDGR

Accounts Payables · Q3 FY2026 · quarter ended Sep 2026

Accounts payables turns negative

Q3 FY2026 accounts payables was -$2.37M, compared with $435K a year earlier. Trailing-twelve-month accounts payables was -$1.28M. Over 3 fiscal years it compounded at -8.3% a year.

Context

  • Accounts payables amounted to 0.4% of revenue in FY2025, down 2.6 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly accounts payables holds near -$2.37M or moves back toward the trailing-twelve-month quarterly average of -$319.5K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$2.37M+50.5% QoQ
Last fiscal yearDec 2025
$908K+114.8% YoY
LTMSep 2026
-$1.28M-35.4% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-644.6%——
1 year+114.8%——
3-year CAGR-8.3%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
908K USD
Year-over-year change
+114.8%

Accounts Payables vs competitors

How SDGR compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -35.4% is the 4th highest of 8, against a peer median of -56.4%.
  • Accounts payables amounts to 0.5% of revenue for SDGR, versus a peer median of 2.5%.
SDGR Competitors
Accounts Payables for SDGR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CERTCertara, Inc.LTM Mar 2026$10.67M USD+138.4%—2.5%
ABCLAbCellera Biologics Inc.LTM Sep 2026$7.53M USD+229.2%+48.0%11.1%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$7.04M USD-374.8%—68.0%
GENBGenerate Biomedicines, Inc.FY2025$2.13M USD-160.9%—6.7%
VEEVVeeva Systems Inc.LTM Jul 2026$2.07M USD-56.4%-34.3%0.1%
SDGRSchrödinger, Inc.LTM Sep 2026$1.28M USD-35.4%-8.3%0.5%
LTRNLantern Pharma Inc.LTM Mar 2026$884.66K USD-352.6%——
SLPSimulations Plus, Inc.LTM Feb 2026$403K USD+352.8%-6.6%0.5%
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$131.02K CAD—-8.7%0.7%
Peer median (excluding SDGR) —-56.4%-7.7%2.5%

Competitors are the stored peer set for SDGR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(101.22M)(149.19M)40.72M(187.12M)(103.27M)
Depreciation & Amortization2.85M4.34M5.55M6.16M6.02M
Deferred Income Tax00000
Stock-Based Compensation26.49M39.63M47.84M49.9M43M
Change in Working Capital4.68M(21.38M)(22.55M)(13.04M)118.17M
Accounts Receivables(5.51M)(27.95M)(20.03M)(166.22M)150.94M
Inventory00000
Accounts Payables(411K)1.18M7.32M(6.12M)908K
Other Working Capital10.6M5.39M(9.85M)159.3M(33.68M)
Other Non-Cash Items(3.46M)6.91M(208.29M)(13.27M)(50.02M)
Operating Cash Flow(70.67M)(119.68M)(136.73M)(157.37M)13.9M
Capital Expenditures(7.17M)(8.01M)(13.4M)(7.31M)(1.44M)
Acquisitions (Net)0(7.03M)(4.13M)45.73M0
Purchases of Investments(418.5M)(271.47M)(320.62M)(251.34M)(312.96M)
Sales of Investments408.48M364.71M383.97M361.76M372.3M
Other Investing Activities375K11.83M147.21M00
Investing Cash Flow(16.81M)90.02M193.03M148.84M57.9M
Debt Repayment00(19K)(58K)(58K)
Common Stock Issued0008.87M2.99M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities7.95M2.11M9.07M1.31M0
Financing Cash Flow7.95M2.11M9.05M10.12M2.93M
Effect of Forex Changes00000
Net Change in Cash(79.53M)(27.55M)65.35M1.59M74.73M
Free Cash Flow(77.84M)(127.7M)(150.14M)(164.68M)12.46M

Schrödinger, Inc.

NASDAQ:SDGR

Intrinsic Alpha fair value

Locked

Current Price

$27.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.